GlassScriptPhysician profile
Laura P Morrison
NPI 1801655006
$850.29
in general payments reported to CMS, 2019-2025
13 companies · $530 in 2025
The $530 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $320 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $164.51 | 2024-2025 | Tarpeyo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.32 | 2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $90.79 | 2024-2025 | Jynarque, Abilify Asimtufii |
| Travere Therapeutics, INC. | $78.34 | 2025 | |
| Vifor Pharma, INC. | $72.57 | 2024-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $71.78 | 2025 | Acthar, Terlivaz |
| Lilly USA, LLC | $62.55 | 2024-2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $55.37 | 2025 | Yorvipath |
| Apellis Pharmaceuticals, INC. | $34.69 | 2025 | Empaveli |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.03 | 2024 | |
| Scpharmaceuticals INC. | $19.69 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.66 | 2024 | |
| Alexion Pharmaceuticals, INC. | $13.99 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.